Open Access

Evaluation of circulating vascular endothelial growth factor and its soluble receptors in patients suffering from persistent allergic rhinitis

  • E. Koczy-Baron1,
  • A. Grzanka2,
  • J. Jochem3,
  • R. Gawlik4 and
  • A. Kasperska-Zajac2Email author
Allergy, Asthma & Clinical Immunology201612:17

https://doi.org/10.1186/s13223-016-0124-2

Received: 26 November 2015

Accepted: 23 March 2016

Published: 27 April 2016

Abstract

Background

Overexpression and enhanced release of vascular endothelial growth factor (VEGF) have been detected in various types of allergic inflammation, including asthma.

Aim

To further evaluate the pattern of systemic release of VEGF in atopic allergy, free circulating VEGF was measured in patients with persistent allergic rhinitis (PAR).

Methods

The concentrations of VEGF and its soluble receptors (sVEGF-R1 and VEGF-R2) in plasma were measured in patients with PAR sensitized to house dust mites and the healthy subjects.

Results

No significant differences were found between PAR patients and healthy subjects with respect to plasma levels of VEGF and its receptors.

Conclusions

It seems that free circulating VEGF may not be elevated in PAR patients. Moreover, on the basis of the present study as well as the earlier ones, it appears likely that systemic release of VEGF varies among patients with distinct clinical manifestation of atopy; may depend on severity/activity and the extent of inflammatory response.

Keywords

Allergic rhinitisVascular endothelial growth factorVEGF receptorsHouse dust mitePlatelet-poor plasma

Background

It has been indicated that vascular endothelial growth factor (VEGF) is a multifunctional cytokine, which plays a role in the pathogenesis of immune-inflammatory reactions [1, 2]. VEGF is a powerful enhancer of vascular permeability and its activity is 50,000 times more potent than histamine [3]. In addition, VEGF may be released by different cells associated with allergic inflammation of the airways, including mast cells upon activation via the Fcε receptor I (FcεRI) [2, 46].

Interestingly, it has been demonstrated that dust-mite allergen may stimulate airway cells to increased VEGF secretion [7], which may play an important role in the modulation of eosinophilic inflammation [8]. There have been several reports describing association between VEGF and allergic airway inflammation. However, data regarding a role of VEGF in the upper-airway allergic diseases are scarce. In the present study, we investigated plasma VEGF concentration in patients with allergy to house dust mites, suffering from persistent allergic rhinitis (PAR) in the absence of asthma symptoms.

Methods

Sixteen patients with moderate to severe PAR (untreated, newly diagnosed) without any history of asthmatic symptoms (seven males, nine females; aged 18–36 years; median 23 years) were enrolled into the study.

They had positive skin tests to Dermatophagoides pteronyssinus and Dermatophagoides farinae extract and positive serology (specific IgE = class 2 or higher) as well as negative response to all other common aeroallergens: pollens (grasses, cereals, trees and weeds), moulds (Alternaria, Cladosporium, Aspergillus, Penicillium), animal danders (comprising dog, cat, rabbit and guinea pig).

The clinical diagnosis of allergic rhinitis was performed according to criteria reported in the ARIA document.

The patients were compared with 35 healthy non-atopic subjects (20 males, 15 females; aged 18–38 years; median 21 years). None of the subjects had any other concomitant disorders [9].

All the subjects submitted respective written consent and the study was approved by the University Committee of Ethics.

Blood samples and analytical methods

VEGF analysis

Because platelets are potential source of VEGF, we measured VEGF concentration in platelet-poor plasma (PPP) according to method described previously [9].

VEGF concentrations were determined using the enzyme-linked immunosorbent assay (ELISA) (Quantikine R&D Systems Inc. Minneapolis, MN USA). The detection limits were 9.0 pg/ml. Values below 9 pg/ml were equalized to zero.

sVEGF-R1 and sVEGF-R2 analyses

sVEGF-R1 and sVEGF-R2 concentrations were performed in the plasma collected, using EDTA as an anticoagulant. The cytokines concentrations were assayed by specific, commercially available, ELISA assay kits (Quantikine R & D Systems Inc., Minneapolis, MN USA) in accordance with the manufacturer’s instructions. The sensitivity of the assay for VEGF-R1 and sVEGFR-2 was 3.0 and 5 pg/ml, respectively.

Skin prick tests

Allergic status was evaluated using a panel of common inhalant (Allergopharma, Reinbeck, Germany). The skin wheal-flare reaction was read after 15 min and considered positive if the wheal diameter was at least 3 mm larger than one formed by the control substance.

Other laboratory investigations

The specific IgE to D. farinae and D. pteronyssinus were measured by ELISA using a commercial kit (Allergopharma, Reinbeck, Germany) according to the manufacturers’ instructions.

Statistical analysis

Data were delivered as medians and interquartile range (IQR). All the statistical evaluations were performed by Mann–Whitney U test. The correlations between parameters were measured with Spearman rank test. The results were considered significant when P < 0.05.

Results

No significant differences were found between PAR patients and healthy subjects with respect to plasma levels of VEGF and its receptors (Table 1; Fig. 1). There were no significant correlations between values of VEGF and specific IgE to D. farinae and D. pteronyssinus (r = 0.244 and r = 0.165, p > 0.05, respectively).
Table 1

Plasma concentration of VEGF and its receptors in patients with PAR and healthy subjects

Parameters (units)

PAR (n = 16) median (IQR)

Healthy subjects (n = 35) median (IQR)

Significance

VEGF (pg/ml)

21.3 (0.0–35.8)

17.2 (0.0–48.8)

p > 0.05

sVEGF-R1 (pg/ml)

40.8 (26.4–70.2)

35.8 (21.7–60.3)

p > 0.05

sVEGF-R2 (pg/ml)

7247.5 (4780–14,960)

7470 (3740–12,765)

p > 0.05

n number; PAR persistent allergic rhinitis; IQR interquartile range

Fig. 1

Plasma VEGF concentration in the control group and patients with persistent allergic rhinitis PAR

Discussion

Atopic diseases like asthma, rhinitis, and atopic dermatitis (AD) are characterised by local changes at the site of allergic processes, as well as systemic immune-inflammatory response. Similarities should be noted between various atopic diseases, but there are also differences, regarding the profiles of mediators released into the systemic circulation [10].

So far, it has been reported that VEGF levels are increased in induced sputum and plasma/serum of asthmatics; its overproduction may be implicated in chronic inflammation, asthma exacerbation, and the airway remodeling [11, 12]. In addition, it has been reported that patients with AD may show significantly increased concentration of VEGF in PPP [9]. It has been demonstrated that the vascular permeability of nasal mucosa was increased by VEGF [13] and this cytokine level in nasal discharge was significantly higher in patients with allergic rhinitis sensitized by house dust mites and pollens than in nonallergic rhinosinusitis [14, 15]. In addition, VEGF serum concentrations were significantly lower in asymptomatic pollen-dependent AR patients studied outside the pollen season than in normal individuals. Interestingly, the VEGF concentrations increased after sublingual immunotherapy and were similar to values of normal subjects [16, 17]. We did not find any significant differences in plasma levels of VEGF and its receptors between PAR patients sensitized to house dust mites and the healthy subjects, suggesting that free circulating VEGF may not be elevated in the persistent allergy. On the basis of our own results as well as those reported by Ciprandi et al. [16, 17], it may be suggested that permanent exposure to allergens, such as AR—induced by persistent allergy (due to mites, mould or danders) or related to allergen immunotherapy are associated with normal VEGF concentration. However, confirmation of such hypothesis would demand evaluation of VEGF in symptomatic patients with seasonal AR induced by pollens during the pollen season.

These findings, in conjunction with earlier data, indicate that differences may exist in systemic VEGF release between patients with distinct clinical manifestation of atopy.

Different cells involved in the pathogenesis of allergic inflammation are able to synthesize and release VEGF. Among them important storage site is formed by the platelets, which release VEGF upon activation in vivo. The measurement of VEGF concentration in PPP is more reliable to assess in vivo free circulating VEGF, which is released from platelets and white blood cells during clotting formation [18].

It has been reported that platelet activation measured by plasma concentration of platelet factor 4 and beta-thromboglobulin is increased in AD patients, asthma, but not in allergic rhinitis and urticaria [10, 1922]. Because platelets are important sources of VEGF in the circulation, these findings have confirmed our earlier observations showing that enhanced platelet release reaction is not a phenomenon accompanying chronic allergic rhinitis.

Conclusions

Contrary to the previous studies indicating that VEGF level was increased in plasma of allergic patients suffering from asthma and atopic dermatitis, it seems that free circulating VEGF may not be elevated in PAR patients.

Moreover, on the basis of the present study as well as the earlier ones, it appears likely that systemic release of VEGF varies among atopic patients and may depend first of all on severity/activity and the extent of inflammatory response.

Abbreviations

AD: 

atopic dermatitis

ELISA: 

enzyme-linked immunosorbent assay

Fcε receptor I: 

FcεRI

PPP: 

platelet-poor plasma

PAR: 

persistent allergic rhinitis

VEGF: 

vascular endothelial growth factor

Declarations

Authors’ contributions

EKB: conceived and designed the study, contributed to data analysis and interpretation as well as wrote the manuscript. AG&RG: collected samples and provided clinical data, JJ: contributed to statistical data analysis and reviewed the manuscript. AKZ: supervised the study as well as reviewed the manuscript. All authors read and approved the final manuscript.

Acknowledgements

This study was supported by a research Grant from the Committee for Scientific Research (KNW-6501-51/08).

Competing interests

The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Dermatology and Venerology
(2)
Department of Internal Diseases, Dermatology and Allergology, SMDZ in Zabrze, Medical University of Silesia
(3)
Departament of Basic Medical Sciences, Medical University of Silesia
(4)
Clinical Department of Internal Diseases, Allergology and Clinical Immunology, SMDZ in Zabrze, Medical University of Silesia

References

  1. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond). 2005;109:227–41.View ArticleGoogle Scholar
  2. Lee CG, Link H, Baluk P, Homer RJ, Chapoval S, Bhandari V, Kang MJ, Cohn L, Kim YK, McDonald DM, Elias JA. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat Med. 2004;10:1095–103.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Senger DR, Connolly DT, Van de Water L, Feder J, Dvorak HF. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 1990;50:1774–8.PubMedGoogle Scholar
  4. Gruber BL, Marchese MJ, Kew R. Angiogenic factors stimulate mast-cell migration. Blood. 1995;86:2488–93.PubMedGoogle Scholar
  5. Horiuchi T, Weller PF. Expression of vascular endothelial growth factor by human eosinophils: upregulation by granulocyte macrophage colony-stimulating factor and interleukin-5. Am J Respir Cell Mol Biol. 1997;17:70–7.View ArticlePubMedGoogle Scholar
  6. Boesiger J, Tsai M, Maurer M, Yamaguchi M, Brown LF, Claffey KP, Dvorak HF, Galli SJ. Mast cells can secrete vascular permeability factor/vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of fc epsilon receptor I expression. J Exp Med. 1998;188:1135–45.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Capetandes A, Zhuang M, Haque FN, Xie L, Frieri M. Vascular endothelial growth factor is increased by human pulmonary cells stimulated with Dermatophagoides sp. extract. Allergy Asthma Proc. 2007;28:324–30.View ArticlePubMedGoogle Scholar
  8. Feistritzer C, Kaneider NC, Sturn DH, Mosheimer BA, Kähler CM, Wiedermann CJ. Expression and function of the vascular endothelial growth factor receptor FLT-1 in human eosinophils. Am J Respir Cell Mol Biol. 2004;30:729–35.View ArticlePubMedGoogle Scholar
  9. Koczy-Baron E, Jochem J, Kasperska-Zajac A. Increased plasma concentration of vascular endothelial growth factor in patients with atopic dermatitis and its relation to disease severity and platelet activation. Inflamm Res. 2012;61:1405–9.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Kasperska-Zajac A, Rogala B. Platelet activation during allergic inflammation. Inflammation. 2007;30:161–6.View ArticlePubMedGoogle Scholar
  11. Asai K, Kanazawa H, Kamoi H, Shiraishi S, Hirata K, Yoshikawa J. Increased levels of vascular endothelial growth factor in induced sputum in asthmatic patients. Clin Exp Allergy. 2003;33:595–9.View ArticlePubMedGoogle Scholar
  12. Lee KY, Lee KS, Park SJ, Kim SR, Min KH, Choe YH, Lee YC. Clinical significance of plasma and serum vascular endothelial growth factor in asthma. J Asthma. 2008;45:735–9.View ArticlePubMedGoogle Scholar
  13. Matsune S, Ohori J, Yoshifuku K, Kurono Y. Effect of vascular endothelial growth factor on nasal vascular permeability. Laryngoscope. 2010;120:844–8.View ArticlePubMedGoogle Scholar
  14. Matsune S, Ohori J, Sun D, Yoshifuku K, Fukuiwa T, Kurono Y. Vascular endothelial growth factor produced in nasal glands of perennial allergic rhinitis. Am J Rhinol. 2008;22:365–70.View ArticlePubMedGoogle Scholar
  15. Benson M, Carlsson B, Carlsson LM, Wennergren G, Cardell LO. Increased expression of vascular endothelial growth factor-A in seasonal allergic rhinitis. Cytokine. 2002;20:268–73.View ArticlePubMedGoogle Scholar
  16. Ciprandi G, Murdaca G, Colombo BM, De Amici M, Marseglia GL. Serum vascular endothelial growth factor in allergic rhinitis and systemic lupus erythematosus. Hum Immunol. 2008;69:510–2.View ArticlePubMedGoogle Scholar
  17. Ciprandi G, Colombo BM, Murdaca G, De Amici M. Serum vascular endothelial growth factor and sublingual immunotherapy. Allergy. 2008;63:945–6.View ArticlePubMedGoogle Scholar
  18. Wynendaele W, Derua R, Hoylaerts MF, Pawinski A, Waelkens E, de Bruijn EA, Paridaens R, Merlevede W, van Oosterom AT. Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo? Ann Oncol. 1999;10:965–71.View ArticlePubMedGoogle Scholar
  19. Kasperska-Zajac A, Brzoza Z, Rogala B. Seasonal changes in platelet activity in patients with pollen-induced seasonal allergic rhinitis and seasonal asthma. J Asthma. 2008;45:485–7.View ArticlePubMedGoogle Scholar
  20. Kasperska-Zajac A, Rogala B. Markers of platelet activation in plasma of patients suffering from persistent allergic rhinitis with or without asthma symptoms. Clin Exp Allergy. 2005;35:1462–5.View ArticlePubMedGoogle Scholar
  21. Kasperska-Zajac A, Rogala B, Nowakowski M. Assessment of platelet activity, expressed by plasma levels of platelet factor 4 and beta-thromboglobulin in patients with chronic idiopathic urticaria. Exp Dermatol. 2005;14:515–8.View ArticlePubMedGoogle Scholar
  22. Kasperska-Zajac A, Rogala B. Platelet function in anaphylaxis. J Invest Allergol Clin Immunol. 2006;16:1–4.Google Scholar

Copyright

© Koczy-Baron et al. 2016

Advertisement